Product Candidate

Thymosin Beta 4 in Dry Eye Syndrome

Dry eye syndrome (DES) is a prevalent condition affecting over 30 million people in the United States alone. It is characterized by ocular surface inflammation, leading to various distressing symptoms such as burning, irritation, severe discomfort, a foreign body sensation in the eye, and blurred or decreased vision. Addressing these symptoms and providing effective relief is crucial for enhancing the quality of life for those suffering from DES.

One promising solution for managing DES is thymosin beta 4 (Tβ4), a naturally occurring peptide with significant therapeutic potential. Tβ4 has shown remarkable benefits in improving the signs and symptoms of dry eye without any toxic effects. Its unique properties make it an exciting candidate for the development of innovative treatments.

The current options for wound healing and anti-inflammatory treatments for the cornea are limited, and some available agents may come with significant complications and side effects. Herein lies the importance of Tβ4 as it offers a novel approach to promoting corneal health and addressing DES-related issues. Tβ4 has been found to enhance corneal epithelial cell migration, facilitating the healing process. Additionally, it decreases the expression of corneal epithelial cytokines and chemokines, such as IL-1β and IL-8, contributing to reducing ocular surface inflammation. Moreover, Tβ4 inhibits corneal PMN (polymorphonuclear leukocytes) infiltration and adhesion to endothelium, further aiding in managing DES and its associated symptoms.

Björklund Pharma AS recognizes the immense potential of Tβ4 and is dedicated to advancing its product development. By focusing on Tβ4, the company aims to introduce cutting-edge therapies that can effectively alleviate the burden of dry eye syndrome and enhance ocular health and comfort for millions of individuals.

References

PubMed articles: https://bit.ly/3Rw9BxC